Gestational diabetes mellitus (GDM) is a common complication of pregnancy that is characterized by glucose intolerance, leads to dyslipidemia, and is aggravated by obesity. Cholesterol is taken up by the placenta as part of lipoproteins through the scavenger receptor class B type I receptor (SRBI), low-density lipoprotein receptor (LDLR), and very low density lipoprotein receptor (VLDLR), and its efflux is then mediated by ABCA1 and ABCG1. PCSK9 is involved in the degradation of LDLR and VLDLR. The goal of this study was to evaluate the impact of GDM and prepregnancy body mass index (BMI) on cholesterol transport through the modulation of the expression of several key players. Human full-term placenta, maternal, and venous cord blood samples were obtained at delivery from normalweight women without GDM (n ¼ 10), normal-weight women with GDM (n ¼ 6), and overweight/obese women with GDM (n ¼ 6). Lipids (total cholesterol, high-density lipoprotein, lowdensity lipoprotein, triglycerides, free fatty acids, apolipoprotein A1, apolipoprotein B100) levels were evaluated in blood samples. Messenger RNA and protein expression levels (LDLR, VLDLR, SRBI, ABCA1, ABCG1, proprotein convertase subtilisin/ kexin type 9, liver x receptors, peroxisome proliferator-activated receptors) were assessed in human full-term placenta, respectively, by real-time RT-PCR and Western blots. Lipoprotein lipase activity was evaluated using a commercial kit on tissue homogenates. Overall, our study demonstrates that GDM affects the maternal and neonatal lipid profiles as well as different key players of placental cholesterol transfer from the maternal to the fetal circulation, depending on the maternal BMI. These changes could affect the fetal metabolism and predispose the fetus to future metabolic diseases.
INTRODUCTION
Gestational diabetes mellitus (GDM) is defined as a carbohydrate intolerance that begins or is first recognized during pregnancy. The prevalence of GDM, which affects between 1% and 14% of pregnancies, is increasing at an alarming rate in Western countries, possibly reflecting the rise of obesity worldwide [1] . Indeed, the risk of GDM is higher in overweight or obese women compared to lean or normalweight women [2] . Obesity and GDM not only increase the risk of adverse pregnancy and infant outcomes; they also constitute strong risk factors for the development of obesity, impaired glucose tolerance, and type 2 diabetes later in life in the child [3] . Moreover, women with a history of GDM are at risk of developing permanent diabetes (mostly type 2) within 5-10 yr after delivery [4] .
The mechanisms by which obesity and/or GDM may lead to health problems later in life in the offspring are not fully understood. GDM is associated with an overstated insulin resistance and an increased placental transport of glucose and other nutrients [1] . Disturbances in lipoprotein metabolism with a tendency toward hypercholesterolemia have also been observed in GDM pregnancies [5] . Cholesterol (CHOL) is an essential component for placental and fetal development [6] . Evidence suggests that abnormal maternal CHOL levels can have a detrimental effect on fetal development, possibly as a consequence of changes in fetal or placental metabolism. For example, fetuses of hypercholesterolemic women have an increase rate of aortic fatty streaks [7] . In humans, fetal tissues have the capacity for de novo CHOL synthesis [8] . However, the high CHOL demand in fetal tissues is not fully satisfied by endogenous mechanisms. CHOL is also taken up by the placenta in the maternal circulation as part of lipoproteins through receptor-dependent or -independent transport [6] . Lipoproteins receptors expressed by the human full-term placenta include the low-density lipoprotein receptor (LDLR), the very low density lipoprotein/apolipoprotein (apo) E receptor (VLDLR), and the scavenger receptor class B type I (SRBI) [9] [10] [11] . LDLR binds and internalizes apoB-and apoEcontaining lipoproteins, mostly LDL particles, which represent 60%-70% of circulating plasma CHOL in humans. VLDLR is the main endocytic receptor binding to apoE-containing lipoproteins. Internalized lipoproteins associated with LDLR and VLDLR are then degraded by the endosome/lysosome pathway, and the receptor is either recycled back to the cell surface or degraded by the proprotein convertase subtilisin/ kexin type 9 (PCSK9) [12] . SRBI is involved mostly in the selective uptake of lipoproteins associated with cholesteryl esters in a process that does not implicate, contrarily to LDLR and VLDLR, lysosomal degradation of lipoproteins [13] . Intracellular CHOL is then either used by the placenta or transferred to the fetus. Lipoproteins also contain triglycerides that are hydrolyzed by the lipoprotein lipase (LPL) before being internalized and esterified to form a free fatty acids (FFA) reserve in the placenta [14] . The mechanisms of CHOL transfer from the maternal to the fetal circulation are not well defined. Two members of the ATP-binding cassette (ABC) family of transporters, ABCA1 and ABCG1, are known to efflux CHOL to apoAI, apoE, and HDL particles in trophoblasts and placental endothelial cells [15, 16] . Other ABC transporters are expressed in the human full-term placenta, such as ABCB1 and ABCG2, but are involved mostly in maternal-fetal transport of drugs and endogenous toxins to protect the fetus [17, 18] . Moreover the expression of ABCA1 and other genes involved in CHOL homeostasis (e.g., ABCG1, LDLR, PCSK9) is modulated by intracellular CHOL levels via the activation of the sterol response element-binding proteins (SREBP) 1 and 2, the liver x receptors (LXR), and/or the peroxisome proliferator-activated receptors (PPAR) [19, 20] .
We hypothesize that GDM affects differently placental CHOL transport according to the maternal body mass index (BMI) by modulating the expression of the lipoprotein receptors LDLR, VLDLR, and SRBI and the ABC transporters ABCA1 and ABCG1. Thus, this study was designed to characterize the effect of GDM on maternal circulating lipids on the expression of lipoprotein receptors and ABC transporters in the human full-term placenta of normal-weight and overweight/obese women with GDM. This study will provide better understanding of the pathways involved in CHOL homeostasis in GDM pregnancies.
MATERIALS AND METHODS

Subjects
Women were recruited during their first prenatal visit (before their 10th week of pregnancy) at the Centre Hospitalier de l'Université de Montréal (CHUM, Hô pital Saint-Luc, Montréal, QC, Canada) or at the Clinique Fidès (Montreal, QC, Canada). Each participant signed an informed consent form and completed a social-medical interview-administrated questionnaire. The study was conducted with the approval of the Université du Québec à Montréal and of the CHUM ethics committees for research on human subjects. Screening for GDM (between 24 and 32 wk of pregnancy) was done according to the CHUQ and CHUM protocol with the 50-g glucose challenge test [21, 22] . Subjects with serum glucose values equal or higher than 7.8 mmol/L were tested with the 100-g oral glucose tolerance test. Finally, data relative to the weight (kg) and height (cm) of the newborns were collected. Based on the World Health Organization criteria, women were considered as normal weight with a BMI between 18.5 and 24.9 kg/m 2 and as overweight/ obese with a BMI .26 kg/m 2 .
Lipid Assays
Blood was collected in Vacutainer gel tube (BD) from the mother as well as from the venous cord blood at delivery (36-42 wk). Mothers were not fasting. Samples were quickly centrifuged 3500 3 g for 15 min less than 1 h after collection, and plasma was recovered and stored at À208C for further analysis. The plasma levels of total CHOL, low-density lipoproteins (LDL), high-density lipoproteins (HDL), apolipoproteins (apoA1 and apoB100), and triglycerides were individually measured at the Clinical Biochemistry Service of Hôpital Saint-François d'Assise (Québec, QC, Canada) using either the Unicel 36 DX600 Synchron Clinical system (Beckman-Coulter), an Elecsys automate, or a Hitachi 717 device (Roche Diagnostics). Total FFA plasma levels were determined using the Free Fatty Acids Half-Micro Test (Roche Diagnostics) according to the manufacturer's instructions.
Tissue Samples
Placentas, obtained from vaginal delivery, were immediately immersed in Dulbecco modified Eagle medium (Sigma) containing antibiotics (0.12 mg/ml penicillin, 5 lg/ml amphotericin, 50 lg/ml gentamycin; Invitrogen) and NaHCO 3 (90 mg/ml). The amnion, chorion, and decidual layers were removed. Villous tissue was cut into approximately 5-cm 2 pieces and kept at À808C for further use.
RNA Extraction and Real-Time RT-PCR
Total RNA was extracted from placental tissue using the High Pure RNA Tissue Kit (Roche Diagnostics) and reverse transcribed (500 ng) using the MMLV Reverse Transcriptase (Sigma Aldrich) and Oligo-dT primers (Roche Diagnostics) according to the manufacturer's instructions. Real-time RT-PCR runs were performed on a LightCycler 480 Instrument (Roche Diagnostics) using the 480 SYBR Green I Master kit (Roche Diagnostics) and 0.5 lM of both sense and antisense primers. Primers sequences were designed with PrimerBlast based on sequences available in GenBank (National Center for Biotechnology Information) and are described in Table 1 . Negative controls and melting curves were performed to ensure the lack of contamination and the specificity of the amplification. The expression of each target gene was normalized to the expression of each reference gene (GAPDH, HPRT1) [23] . The geometric mean of the resulting ratios was then calculated to evaluate relative expression of each gene of interest [24] .
Total Protein Extraction
Placental tissues were homogenized using a Polytron Tissue homogenizer PT 3000 (Brinkmann) in ice-cold hypertonic buffer (125 mM Tris-HCl, 2 mM CaCl 2 , 1.4% [v/v] Triton X-100, pH 8.0). The Complete mini EDTA-free antiprotease cocktail (Roche Diagnostics) was previously added to the buffer. Homogenates were kept 30 min at 48C and centrifuged at 10 000 3 g for 25 min at 48C. Supernatants were collected, aliquoted, and stored at À808C until further use. The BCA protein assay kit (Pierce Biotechnology) was used to evaluate the protein content of the samples.
Western Blot Analyses
Fifty micrograms of proteins diluted in sample buffer were heated at 958C for 5 min, resolved on a SDS-PAGE, and electroblotted onto PDVF membranes (Millipore). Membranes were then blocked in TBS-T (20 mM Tris Base, pH 7.6, 137 mM NaCl, 0.1% Tween-20) containing 5% skim milk 1 h at room temperature (SRBI, VLDLR, ABCA1, ABCG1, PCSK9, PPARa, PPARc, LXRa, LXRb) or overnight at 48C (LDLR). Thereafter, membranes were incubated with primary antibodies 1 h at room temperature (LDLR) or overnight at 48C (SRBI, VLDLR, ABCA1, ABCG1, PCSK9, PPARa, PPARc, LXRa, LXRb). The primary antibodies used were a rabbit anti-LDLR (Fitzgerald; 1:500), a rabbit anti-SRBI antibody (Novus Biological; 1:2500), a goat anti-ABCG1 (Santa Cruz Biotechnology; 1:1000), a mouse anti-VLDLR (Santa Cruz Biotechnology; 1:125), a mouse anti-ABCA1 (Santa Cruz Biotechnology; 1:1000), a goat anti-PCSK9 (Novus Biological; 1:2500), a rabbit anti-PPARa (Santa Cruz Biotechnology; 1:1000), a mouse anti-PPARc (Santa Cruz Biotechnology; 1:1000), a rabbit anti-LXRa (Sigma Aldrich; 1:1000), and a rabbit anti-LXRb (Sigma Aldrich; 1:1000). Blots were washed with TBS-T and probed with anti-mouse, anti-rabbit, or anti-goat IgG horseradish peroxidase-conjugated secondary antibodies (Cell Signaling; 1:10 000). The detection was performed using the Luminata Forte Western HRP Substrate (Millipore) and visualized by autoradiography (Hyperfilm ECL; GE Healthcare). The quantification of the bands was performed with the Quantity One Software (Bio-Rad Laboratories). Normalization was done with Amido Black staining (Sigma Aldrich) [25] .
Quantification of LPL Activity
Tissues were homogenized with a pestle homogenizer in ice-cold extraction buffer (150 mM NaCl, 10 mM Tris, 2 mM EDTA, pH 7.4). Homogenates were centrifuged for 30 min at 10 000 3 g at 48C. LPL enzyme activity was measured in supernatants using a commercial kit (Roar Biomedical) and a SpectraMax M5 (Molecular Devices) according to the manufacturer's instructions. Results were normalized to the amount of protein (nmol/mg of tissue protein) determined using the BCA protein assay kit (Pierce Biotechnology).
Statistical Analyses
Data were expressed as the geometric mean/mean 6 standard error of the mean. Data were analyzed with one-way ANOVA with the Tukey posttest with PRISM 5.01 software (GraphPad Software) after the Kolmogorov-Smirnov normality test was performed to ensure normal distribution of the different data sets. The level of significance was set at P , 0.05. The relationship between two variables was evaluated with the Pearson correlation.
RESULTS
Maternal, Placental, and Neonatal Characteristics
Women participating to this study were separated into three groups: controls (normal-weight women without GDM; 18.5 , BMI , 24.9 kg/m 2 ), normal-weight women with GDM (18.5 , BMI , 24.9 kg/m 2 ), and overweight/obese women with GDM (BMI . 26 kg/m 2 ). The group of overweight/obese women was significantly different from controls in their pregravid BMI, weight gain, and the gestational age but were similar in the maternal age, birth weight, and the placental weight ( Table 2 ). The birth weight for the normal-weight women with GDM was significantly increased compared to controls (Table 2 ). No differences were noted between controls and normal-weight women with GDM for all other characteristics ( Table 2 ). The gestational age and the weight gain were inversely correlated to the BMI (r ¼ À0.5132, P ¼ 0.0146; r ¼ À0.7199, P ¼ 0.0002, respectively).
Maternal and Newborn Plasma Lipid Profiles
Triglycerides were higher in normal-weight mothers with GDM compared to controls, whereas plasma levels of HDL and apoA1 were lower in normal-weight mothers with GDM compared to controls (Table 3) . Overweight/obese women with GDM had lower levels of total CHOL, LDL, and apoB100 levels compared to controls. No changes were noted for total CHOL, LDL, and apoB100 levels between controls and normalweight women with GDM and for triglycerides, HDL, and apoA1 levels between controls and overweight/obese women (Table 3) . Maternal HDL and apoA1 levels were inversely DIABETES AND PLACENTAL CHOLESTEROL TRANSPORT correlated to the birth weight (r ¼ À0.4905, P ¼ 0.0388; r ¼ À0.5715, P ¼ 0.0132, respectively) and positively correlated to the gestational age (r ¼ 0.5432, P ¼ 0.0198; r ¼ 0.4759, P ¼ 0.0459, respectively). Maternal apoB100 levels were inversely correlated to the maternal BMI (r ¼À0.4569, P ¼ 0.0492). No correlations were found between maternal total CHOL and LDL levels and other maternal, neonatal, or placental parameters. In newborns, only FFA levels were lower in normal-weight women with GDM compared to controls (Table 3) ; no correlations were found with maternal, neonatal, or placental characteristics.
Influence of GDM on mRNA and Protein Expression of Lipoprotein Receptors in Human Full-Term Placentas
We compared the expression of SRBI, LDLR, and VLDLR mRNA and proteins in placentas from controls (n ¼ 10), FIG. 1 . Quantification of SBBI, LDLR, and VLDLR mRNA and protein levels in human full-term placentas from control and GDM pregnancies. Quantification for SRBI (A), LDLR (C), and VLDLR (E) mRNA was performed by real-time RT-PCR for controls (n ¼ 10), normal-weight women with GDM (n ¼ 6), and overweight/obese women with GDM (n ¼ 6). The expression level of each interest gene was normalized with two reference genes (GAPDH and HPRT1). Results are expressed as geometric mean 6 SEM. Densitometric analysis of SR-BI (B), LDLR (D), and VLDLR (F) protein levels was performed in controls (n ¼ 10), normal-weight women with GDM (n ¼ 6), and overweight/obese women with GDM (n ¼ 6) after normalization with AmidoBlack staining. Results are expressed as mean 6 SEM. Data were analyzed using one-way ANOVA followed by a Tukey test (*P , 0.05, **P , 0.01).
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FIG. 2.
Quantification of ABCA1 and ABCG1 mRNA and protein levels in human full-term placentas from control and GDM pregnancies. Quantification for ABCA1 (A) and ABCG1 (C) mRNA was performed by real-time RT-PCR for controls (n ¼ 10), normal-weight women with GDM (n ¼ 6), and overweight/obese women with GDM (n ¼ 6). The expression level of each interest gene was normalized with two reference genes (GAPDH and HPRT1). Results are expressed as geometric mean 6 SEM. Densitometric analysis of ABCA1 (B) and ABCG1 (D) protein levels was performed in controls (n ¼ 10), normal-weight women with GDM (n ¼ 6), and overweight/obese women with GDM (n ¼ 6) after normalization with AmidoBlack staining. Results are expressed as mean 6 SEM. Data were analyzed using one-way ANOVA followed by a Tukey test (*P , 0.05, **P , 0.01).
FIG. 3.
Quantification of PCSK9 mRNA and protein levels in human full-term placentas from control and GDM pregnancies. A) Quantification of PCSK9 mRNA was performed by real-time RT-PCR for controls (n ¼ 10), normal-weight women with GDM (n ¼ 6), and overweight/obese women with GDM (n ¼ 6). The expression level of the interest gene was normalized with two reference genes (GAPDH and HPRT1). Results are expressed as geometric mean 6 SEM. B) Densitometric analysis of PCSK9 protein levels was performed in controls (n ¼ 10), normal-weight women with GDM (n ¼ 6), and overweight/ obese women with GDM (n ¼ 6) after normalization with Amido Black staining. Representative Western blots are included. Results are expressed as mean 6 SEM. Data were analyzed using a one-way ANOVA followed by a Tukey test (*P , 0.05).
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normal-weight women with GDM (n ¼ 6), and overweight/ obese women with GDM (n ¼ 6). The placental expression of SRBI mRNA did not change between groups (Fig. 1A) , whereas the expression of SRBI protein was significantly higher in normal-weight women with GDM compared to other groups (Fig. 1B) . The placental expression of LDLR mRNA and protein was significantly higher in normal-weight and overweight/obese women compared to controls (Fig. 1, C and  D) . The placental expression of VLDLR mRNA and protein was significantly higher in overweight/obese women with GDM compared to other groups (Fig. 1, E and F) . The expression of SRBI protein was positively correlated to the placental weight (r ¼ 0.5264, P ¼ 0.0171) and negatively correlated to the apoB100 levels in the newborn (r ¼À0.5170, P ¼ 0.0336). The expression of LDLR mRNA was positively correlated to the placental weight (r ¼ 0.4587, P ¼ 0.0318) and negatively correlated to maternal total CHOL, LDL, and apoB100 levels (r ¼ À0.4815, P ¼ 0.0316; r ¼ À0.4876, P ¼ 0.0292; r ¼À0.5275, P ¼ 0.0168, respectively). The expression of LDL protein was negatively correlated to maternal apoB100 levels (r ¼ À0.5132, P ¼ 0.0294). The expression of VLDLR mRNA was positively correlated to the ponderal index (r ¼ 0.4227, P ¼ 0.05). The expression of VLDLR protein was positively correlated to the BMI (r ¼ 0.05310, P ¼ 0.0133) and negatively correlated to the weight gain (r ¼ À0.5963, P ¼ 0.0043).
Influence of GDM on mRNA and Protein Expression of ABC Transporters in Human Full-Term Placentas
We compared the expression of ABCA1 and ABCG1 mRNA and proteins in placentas from controls (n ¼ 10), normal-weight women with GDM (n ¼ 6) and overweight/ obese women with GDM (n ¼ 6). The placental expression of ABCA1 mRNA did not change between groups ( Fig. 2A) , whereas the expression of ABCA1 protein was significantly lower in normal-weight women and overweight/obese women with GDM compared to controls (Fig. 2B) . The placental expression of ABCG1 mRNA did not change in normal-weight and overweight/obese women with GDM compared to controls (Fig. 2C) , whereas the expression of ABCG1 protein was significantly lower in overweight/obese women with GDM compared to the other groups (Fig. 2D) . No correlations were found between the expression of ABCA1 protein and maternal, neonatal, or placental characteristics or lipid profiles. The expression of ABCG1 protein was negatively correlated to BMI (r ¼ À0.7070, P ¼ 0.0022) and positively correlated to weight gain (r ¼ 0.5493, P ¼ 0.0275).
Influence of GDM on mRNA and Protein Expression of PCSK9 in Human Full-Term Placentas
We compared the expression of PCSK9 mRNA and protein in placentas from controls (n ¼ 10), normal-weight women with GDM (n ¼ 6), and overweight/obese women with GDM (n ¼ 6). The placental expression of PCSK9 mRNA did not change between groups (Fig. 3A) , whereas the expression of PCSK9 protein was significantly lower in normal-weight and overweight/obese women with GDM compared to controls (Fig.  3B ). The expression of PCSK9 protein was positively correlated to LDL levels in the newborn (r ¼ 0.5480, P ¼ 0.0228).
Influence of GDM on LPL Enzyme Activity in Human FullTerm Placentas
LPL activity increased in placentas from GDM pregnancies compared to controls (Fig. 4) . LPL enzyme activity was negatively correlated to neonatal LDL levels (r ¼À0.4850, P ¼ 0.0413) and positively correlated to triglycerides and FFA levels in the newborn (r ¼ 0.4895, P ¼ 0.0392; r ¼ 0.6049, P ¼ 0.0078, respectively).
Influence of GDM on the mRNA and Protein Expression of PPARa, PPARc, LXRa, and LXRb in Human Full-Term Placentas
The placental expression of PPARa and PPARc mRNA did not change between groups (Fig. 5, A and C) . The protein expression of PPARa and PPARc increased and decreased, respectively, in the placentas of overweight/obese women with GDM compared to controls (Fig. 5, B and D) . The expression of LXRa mRNA and protein was significantly higher in overweight/obese women with GDM compared to the other groups, whereas it remained unchanged in normal-weight women with GDM compared to controls (Fig. 5, E and F) . The expression of LXRb mRNA was significantly lower in normalweight and overweight/obese women with GDM compared to controls, whereas the expression of LXRb protein increased only in overweight/obese women with GDM compared to controls (Fig. 5, B and D) . The expression of LXRa mRNA was positively correlated to BMI (r ¼ 0.5510, P ¼ 0.0079) and negatively correlated to maternal age (r ¼ À0.4878, P ¼ 0.0213). No correlation was found between LXRa protein and other parameters. The expression of LXRb mRNA was positively correlated to maternal age (r ¼ 0.4432, P ¼ 0.0442). The expression of LXRb protein was correlated to BMI (r ¼À6275, P ¼ 0.0031) and weight gain (r ¼ 0.5277, P ¼ 0.0168).
DISCUSSION
Hyperlipidemia is commonly observed in normal pregnancy and consists primarily of hypertriglyceridemia with smaller rises in phospholipids and CHOL [26] . Disturbances in   FIG. 4 . LPL expression and activity in human full-term placentas from control and GDM pregnancies. Placental LPL activity (nmol/mg protein) was evaluated controls (n ¼ 10), in normal-weight women with GDM (n ¼ 6) and overweight/obese women with GDM (n ¼ 6). Results are expressed as mean 6 SEM. Data were analyzed using a one-way ANOVA followed by a Tukey test (*P , 0.05).
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FIG. 5. Quantification of PPARa, PPARc, LXRa, and LXRb mRNA and protein levels in human full-term placentas from control and GDM pregnancies. Quantification of PPARa (A), PPARc (C), LXRa (E), and LXRb (G) mRNA was performed by real-time RT-PCR for controls (n ¼ 10), normal-weight women with GDM (n ¼ 6), and overweight/obese women with GDM (n ¼ 6). The expression level of each interest gene was normalized with two reference genes (GAPDH and HPRT1). Results are expressed as geometric mean 6 SEM. Data were analyzed using a one-way ANOVA followed by a Tukey test (*P , 0.05, **P , 0.01). Densitometric analysis of PPARa (B), PPARc (D), LXRa (F), and LXRb (H) protein levels was performed in controls (n ¼ 10), normal-DIABETES AND PLACENTAL CHOLESTEROL TRANSPORT lipoprotein metabolism have also been noted in diabetes with a tendency toward hypertriglyceridemia [27] rather than hypercholesterolemia [28] . Insulin resistance and type 2 diabetes are associated with plasma lipid and lipoprotein abnormalities, which include reduced HDL and increased triglyceride levels [29] . This abnormal lipid profile has been noted in case of GDM compared to control women [30] [31] [32] [33] [34] [35] [36] . These facts are in accordance with our results, where we found a significant increase of triglycerides and a significant decrease of HDL and apoA1 in normal-weight women with GDM compared to control ones. Interestingly, in overweight/obese women with GDM, we rather observed a decreased level of LDL and apoB100 compared to controls, suggesting that GDM affects different pathways of CHOL transport in these two groups. Not surprisingly, we observed increased expression of different lipoprotein receptors in normal-weight women and overweight/ obese women with GDM.
The altered expression of LDLR, SRBI, and VLDLR could be regulated through transcriptional and/or posttranscriptional mechanisms. Several transcription factors are known to regulate directly or indirectly the expression of lipoprotein receptors. Both PCSK9 and the E3 ubiquitin ligase Idol are involved in the degradation of LDLR and VLDLR and are targets of LXRs [1, 2, 4, 24] . A study using mice showed that the inactivation of Pcsk9 increased the level of LDLR protein expression in the liver, accelerating the rate of clearance of circulating CHOL [37] . The increased LDLR protein expression could as well be attributed to the maternal inflammatory status; an increase of placental cytokines IL-1b and TNF-a concentrations has previously been demonstrated in GDM pregnancies [38, 39] . IL-1b has been associated as well with the risk of developing type 2 diabetes [40] . In fact, a study using smooth muscle cells suggests that chronic inflammation may modify cholesterol homeostasis by disrupting LDLR regulation via overexpression of the sterol regulatory element binding protein (SREBP) cleavage-activating protein (SCAP) known to cleave SREBP, thereby enhancing LDL receptor gene expression [41] . SREBP1 also regulates the expression of SRBI [42] . However, the level of mature SREBP1 or SREBP2 expressions does not change in GDM compared to control placentas [39] . SCAP and SREBPs are activated in response to decreased intracellular cholesterol levels, and SCAP activity is regulated by various proteins, such as Insig-1 and Insig-2 [43] . The expression of SCAP, Insig-1, and Insig-2 and their involvement in the SREBP pathway are unknown in the human full-term placenta. However, SCAP and Insig-1 have been detected in the placenta of the Golden Syrian hamster [44] , suggesting a role for these proteins in placental functions. The unaltered expression of SREBP1 and SREBP2 in placentas of GDM pregnancies could thus reflect unchanged intracellular CHOL levels. Other studies have shown that SRBI is regulated by PPARa, PPARc [45, 46] , and TGFb via LXRa [47] . But in our study, the expression of LXRs and PPARs did not change in normal-weight women with GDM. The upregulation of SRBI could be due to other mechanisms of regulation, such as the farnesoid X receptor [48] or the PI3K/AKT pathway [49] . Overall, these results suggest an increased transfer of CHOL from the maternal circulation to the placenta of GDM pregnancies compared to controls through the upregulation of the expression of various lipoprotein receptors, depending on the maternal BMI.
To evaluate if the transfer of this CHOL to the fetal circulation is altered, we looked at the expression of the ABC transporters ABCA1 and ABCG1. It has been shown that knockdown of ABCA1 expression in primary human trophoblasts induces a decreased CHOL efflux to apoA1, whereas knockdown of ABCG1 expression provokes a decreased CHOL efflux to HDL. In addition, both ABCA1 and ABCG1 are expressed on the maternal and fetal sides of the placenta, but studies have shown that ABCA1 is preferentially expressed on the maternal side, whereas ABCG1 is preferentially expressed on the fetal side of the placenta [15] . The decreased expression of ABCA1 and ABCG1 proteins in GDM pregnancies thus suggests that the transfer of CHOL to the fetal and maternal circulation is disrupted in GDM pregnancies. It also implies that the transport of drugs by ABC transporters across the placenta could be affected and that certain GDM treatments based on these transporters could be less efficient than expected [50] . Anger et al. [51] have shown that the placental protein expression of other ABC transporters (MDR1, MRP2, BCRP) is not altered in GDM pregnancies. However, this study has not taken into account the maternal BMI. It is therefore difficult to evaluate if these transporters would be affected by GDM in our groups. The altered expression of ABCA1 and ABCG1 in GDM pregnancies probably involves the LXR pathway since in human trophoblasts ABCA1 and ABCG1 expression is regulated by LXRa/b and not by PPARa/c [15] . However, the exact mechanisms of regulation of ABCA1 and ABCG1 by LXRa/b are unknown and could imply different mediators. Reduced expression of ABCG1 could be part of a compensatory mechanism to limit excessive transfer of CHOL to the fetal circulation; in addition, the decreased expression of ABCA1 could reflect an accumulation of CHOL into the placenta even if the placental weight does not change in GDM pregnancies. This could explain why the levels of total CHOL, HDL, and LDL are not affected in venous cord blood of GDM pregnancies. Utilization of CHOL by the fetal adrenal glands could also influence the levels of circulating lipoproteins. In diabetic animals, the adrenal function is impaired, which could result in a reduced utilization of circulating LDL [52, 53] . However, the increased neonatal levels of FFA and indirectly the increased birth weight in normal-weight women with GDM could be due to the excessive internalization of lipoproteins into the placenta, the increased activity of LPL, and the increased expression of fatty acid carriers, such as CD36 in the case of obesity [54] . Moreover, the increased expression of lipoprotein receptors and the decreased expression of ABC transporters could explain the reduced levels of total CHOL, LDL, HDL, apoA1, and apoB100 in the maternal circulation.
This study has a number of limitations. First, nonfasting samples were used because of the pregnancy itself and to facilitate the collection of both maternal and newborn bloods from the same pregnancy. Second, GDM mothers were treated with insulin to lower their blood sugar levels. This could influence our results. Indeed, studies have shown differences in alteration of the insulin signaling pathway in the placenta between controls and insulin-treated GDM subjects but also between diet-controlled and insulin-managed GDM pregnancies [55] . Moreover, even if diabetic women are treated with insulin, it is possible that their hyperglycemia is not well controlled. However, in our study, normal-weight and overweight/obese women with GDM present mean glucose levels of 3.70 6 0.85 and 4.38 6 0.37 mmol/L, respectively (data not shown) at the end of pregnancy, suggesting that their hyperglycemia is in fact well controlled. In addition, studies have shown that only 20%-30% of diabetic women fail to control their glucose levels during pregnancy [56, 57] .
In conclusion, our study shows that maternal and cord blood lipid profiles are disrupted in the case of GDM. In addition, we demonstrated that cholesterol transfer from the maternal to the fetal circulation via the placenta might be affected by GDM through the modulation of the expression of key players, but the mechanisms involved differ depending on the maternal pregravid BMI. Therefore, it would be important in future studies on GDM to take into account the maternal BMI. Placental protein expression of lipoprotein receptors is modulated in GDM pregnancies, probably as a result of mechanisms implicating PCSK9, whereas ABC transporter expression is probably modulated by LXRa/b. Overall, this study demonstrates that GDM affects placental CHOL homeostasis, which could induce changes in fetal metabolism that could predispose the fetus to future metabolic diseases. Further studies would be important to assess the exact impact of these changes on placental CHOL transport and on the health of the newborn.
